REMSleep Holdings Announces Full Commercial Launch of DeltaWave(TM)
MWN-AI** Summary
REMSleep Holdings, Inc. (OTCQB: RMSL) has announced the complete commercial launch of its DeltaWave™ nasal pillow system across all U.S. distribution channels, marking a significant milestone after a three-year developmental journey. With FDA 510(k) clearance expanded on January 15, followed by Medicare PDAC coding approval on January 21, all regulatory prerequisites for full-scale distribution have been met. The launch is geared towards durable medical equipment (DME) providers, institutional sales, physicians, and patients, capturing both home and clinical settings.
The DeltaWave system utilizes patented Direct Airflow Technology designed to mitigate discomfort, thus encouraging longer therapy compliance—an ongoing challenge in sleep medicine where 30% to 50% of CPAP patients discontinue use within the first year due to mask discomfort. REMSleep's comprehensive product line includes a starter kit with multiple nasal pillow sizes, single pillow systems for resupply, a nasal interface option, and various accessories, all now approved for reimbursement by Medicare and private insurers.
The company’s strategic rollout involved deploying an independent sales force across 48 states, activating enterprise ERP systems, and validating product reception through zero-return rates from early DME partners during a soft launch phase. CEO Thomas Wood emphasized the company’s resolve to finally bring a solution to market that addresses therapy-compliance issues.
The DeltaWave system’s introduction in institutional settings such as hospitals and rehabilitation centers presents further opportunities for market penetration as patients acclimate to the product. REMSleep Holdings is set to continue releasing operational updates as it navigates its commercialization efforts through 2026.
MWN-AI** Analysis
REMSleep Holdings, Inc. (OTCQB: RMSL) is poised for significant market impact following the full commercial launch of its DeltaWave™ Nasal Pillow System. This launch represents the culmination of a strategically crafted three-year development process, designed to address the high rates of non-compliance among CPAP patients—a pervasive challenge in sleep medicine.
The DeltaWave system is differentiated by its patented Direct Airflow Technology, which enhances patient comfort and compliance. Given that compliance rates can vary from 50% to 70%, DeltaWave’s potential to improve user experience positions it strongly in a market ripe for innovation. With the recent FDA clearance expansions and PDAC coding approvals, REMSleep has laid a robust foundation for revenue generation through diverse distribution channels, including both DME providers and institutional healthcare facilities.
Investors should be attentively monitoring key performance indicators as REMSleep transitions into its profitable phase. The firm’s proactive establishment of an independent sales force across 48 states and the deployment of a sophisticated ERP system assure stakeholders of an organized approach to scaling operations effectively. Early adoption by DME partners has been encouraging, with validation reported from initial product trials.
The introduction of DeltaWave into various healthcare settings also opens the door to institutional partnerships, providing substantial long-term revenue opportunities as patients experience the product before possibly opting for personal purchase. The clear value proposition and clinical differentiation over traditional masks may attract a steady stream of repeat business for DME providers.
Overall, REMSleep Holdings presents itself as a promising investment, particularly as it embarks on this crucial commercialization phase. As the company continues to update the market through Q1 and Q2 2026, keeping a close eye on sales metrics and market adoption will be key for potential investors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Nasal Pillow System All Configurations and Accessories Now Available to DME Providers, Physicians, and Patients Nationwide - The Last Piece of a Three-Year Build Has Clicked Into Place
BLACKSHEAR, GA - February 24, 2026 (NEWMEDIAWIRE) - REMSleep Holdings, Inc. (OTCQB: RMSL), developer of the FDA-cleared DeltaWave™ nasal pillow system, today announced the full commercial launch of the DeltaWave product portfolio across all U.S. distribution channels, including durable medical equipment (DME) companies, and institutional sales.
This isn’t a soft launch or a limited rollout. It’s the real thing.
With expanded FDA 510(k) clearance secured on January 15 and Medicare PDAC coding approved for every product configuration on January 21, the final regulatory prerequisites for nationwide distribution are now in place. REMSleep is fully open for business.
How We Got Here
Shareholders who’ve followed along over the past several months know this moment didn’t happen overnight. The company has been methodically building the foundation required to support a commercial launch that could actually scale:
- December 2025: Enterprise ERP systems activated, nationwide independent sales force deployed across 48 states, product inventory received
- December 2025: Zero-return, repeat-order results validated from early adopting DME partners during soft launch
- January 7, 2026: Expanded 510(k) clearance (K253939) received - DeltaWave’s indicated use broadened to BiPAP, institutional settings, hospitals, long-term care, and sleep labs
- January 21, 2026: Full PDAC/HCPCS coding approval received for every DeltaWave configuration, enabling DME providers to bill Medicare and private insurers
- February 2026: Full commercial launch, all channels, all configurations
That’s the arc. Infrastructure first. Clearances second. Launch third.
What’s in the Portfolio
The DeltaWave Nasal Pillow System is built around a patented Direct Airflow Technology - a design that reduces the pressure and airflow sensation patients feel at the nasal interface. It’s a unique engineering design with real clinical impact: patients who feel less effects of pressure tend to stay on therapy longer. That’s the therapy compliance problem this product was built to solve.
The full commercial portfolio includes:
- Starter Kit - includes all three nasal pillow sizes in a single package, simplifying initial patient setup and fitting
- Single Pillow Systems - ideal for resupply
- Nasal Interface (without headgear) - an additional resupply configuration
- Full Accessories Suite - complete range of replacement components
The PDAC coding approvals cover every one of these configurations for Medicare and private payor billing. DME providers now have the codes, the inventory access, and the clinical rationale to bring DeltaWave into their product mix.
What This Means for the Market
CPAP compliance is a persistent problem in sleep medicine. Somewhere between 30 and 50 percent of patients prescribed therapy abandon it within the first year, and mask discomfort is consistently cited as a top reason. DME providers deal with this daily - patients calling to return masks, asking for alternatives, or simply disappearing from follow-up.
DeltaWave’s positioning as a rescue mask alternative gives providers a clinically differentiated option when their standard formulary isn’t working. That’s a concrete value proposition, that has real world application.
The expanded clearance also opens institutional channels - hospitals, long-term care facilities, rehabilitation centers, and sleep labs - that weren’t accessible under the original 510(k) language. Those channels tend to introduce the solution to patients at the begining of therapy. Once patients become comfortable with the mask they will continue to reorder providing downstream revenue opportunities for our DME partners.
Thomas Wood, CEO and Founder
“After years of funding this product personally through FDA, patents, clinical testing, and every operational hurdle you can imagine - it’s good to say we’re launching finally. Not 'preparing to launch,' not 'targeting a launch' - launching. The product works. The market needs it. The infrastructure is ready. Now we sell.”
Wood added: “DeltaWave was designed from day one to give patients a more comfortable breathing experience - so they stay on therapy and actually benefit from it. That design goal hasn’t changed. What’s changed is that we now have everything in place to put it in their hands at scale.”
Ordering and Availability
The DeltaWave Nasal Pillow System is available now through REMSleep’s direct sales channels. DME providers, physicians, and patients can reach the sales team at sales@remsleep.com or visit www.remsleep.com for product specifications, pricing, and ordering information.
REMSleep will continue providing operational updates on a regular basis as commercialization develops through Q1 and into Q2 2026.
About REMSleep Holdings, Inc.
REMSleep Holdings, Inc. (OTCQB: RMSL) is a medical device company focused on improving outcomes for patients requiring positive airway pressure therapy. The company’s DeltaWave™ nasal pillow system is FDA-cleared for use with CPAP, BiPAP, and other non-invasive positive pressure devices in both home and institutional settings. All DeltaWave products have received PDAC coding approval for Medicare and private insurance reimbursement.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including but not limited to market acceptance of the DeltaWave system across multiple channels and care settings, DME provider adoption rates, the company’s ability to achieve targeted sales volumes, reimbursement practices by private payors, and general market conditions. REMSleep undertakes no obligation to update these forward-looking statements.
Contact:
Thomas Wood, CEO
REMSleep Holdings, Inc.
912-590-2001
twood@remsleep.com
www.remsleep.com
3222 HWY 84 Suite 101, Blackshear, GA 31516
View the original release on www.newmediawire.com
FAQ**
How does REMSleep Holdings Inc RMSL plan to differentiate DeltaWave from competitor products in the nasal pillow market after its full commercial launch?
Given the challenges of CPAP compliance, what strategies does REMSleep Holdings Inc RMSL have in place to ensure DME providers effectively promote and sell the DeltaWave system?
What feedback mechanisms will REMSleep Holdings Inc RMSL implement to gather data on the performance and patient satisfaction of the DeltaWave nasal pillow system post-launch?
How does REMSleep Holdings Inc RMSL intend to leverage its expanded FDA clearances and PDAC coding approvals to maximize distribution across various healthcare settings?
**MWN-AI FAQ is based on asking OpenAI questions about REMSleep Holdings Inc (OTC: RMSL).
NASDAQ: RMSL
RMSL Trading
-1.35% G/L:
$0.0073 Last:
392,592 Volume:
$0.0062 Open:
